A detailed history of Parsons Capital Management Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Parsons Capital Management Inc holds 5,512 shares of VRTX stock, worth $2.25 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
5,512
Previous 5,262 4.75%
Holding current value
$2.25 Million
Previous $2.47 Million 3.93%
% of portfolio
0.17%
Previous 0.17%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

BUY
$460.0 - $505.78 $115,000 - $126,445
250 Added 4.75%
5,512 $2.56 Million
Q2 2024

Jul 19, 2024

BUY
$392.81 - $485.53 $1.02 Million - $1.26 Million
2,591 Added 97.0%
5,262 $2.47 Million
Q1 2024

Apr 22, 2024

BUY
$407.69 - $446.08 $768,087 - $840,414
1,884 Added 239.39%
2,671 $1.12 Million
Q4 2023

Jan 22, 2024

BUY
$343.0 - $410.68 $34,300 - $41,068
100 Added 14.56%
787 $320,000
Q2 2023

Aug 04, 2023

SELL
$314.42 - $351.91 $628 - $703
-2 Reduced 0.29%
687 $241,000
Q1 2023

Apr 17, 2023

BUY
$283.23 - $323.1 $195,145 - $222,615
689 New
689 $217,000
Q4 2021

Feb 07, 2022

SELL
$177.01 - $223.45 $224,448 - $283,334
-1,268 Closed
0 $0
Q3 2021

Nov 09, 2021

SELL
$181.39 - $202.99 $257,573 - $288,245
-1,420 Reduced 52.83%
1,268 $230,000
Q2 2021

Aug 03, 2021

SELL
$187.49 - $221.1 $135,555 - $159,855
-723 Reduced 21.2%
2,688 $542,000
Q1 2021

Apr 28, 2021

SELL
$207.02 - $241.31 $541,978 - $631,749
-2,618 Reduced 43.42%
3,411 $733,000
Q4 2020

Feb 08, 2021

SELL
$207.01 - $276.09 $14,490 - $19,326
-70 Reduced 1.15%
6,029 $1.43 Million
Q3 2020

Oct 29, 2020

BUY
$255.65 - $303.1 $105,327 - $124,877
412 Added 7.24%
6,099 $1.66 Million
Q2 2020

Aug 10, 2020

BUY
$225.48 - $295.8 $77,790 - $102,051
345 Added 6.46%
5,687 $1.65 Million
Q1 2020

May 05, 2020

BUY
$199.77 - $247.81 $1.07 Million - $1.32 Million
5,342 New
5,342 $1.27 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Parsons Capital Management Inc Portfolio

Follow Parsons Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parsons Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Parsons Capital Management Inc with notifications on news.